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doi:10.1016/j.kjms.2010.12.003Abstract We investigated the relationship between renal function and coronary thrombolysis
in myocardial infarction frame count (TFC) in patients with slow coronary flow (SCF). The
patient group was composed of 34 patients with SCF. The control group was made up of 34
well-matched individuals who have normal SCF in their coronary arteries. The coronary flow
rates of all subjects were documented by TFC. Glomerular filtration rate (GFR) and corrected
GFR (cGFR) were calculated by creatinine clearance according to the Cockcroft-Gault formula.
There is no difference in the gender or age of the groups. Blood urea nitrogen and creatinine
were significantly higher in the SCF group compared the control group (blood urea nitrogen:
17 6 mg/dL vs. 14 4 mg/dL, pZ 0.04 and creatine: 0.9 0.1 mg/dL vs. 0.7 0.1 mg/dL,
pZ 0.01). GFR and cGFR were significantly different between the groups (GFR: 92 28 mL/
min vs. 112 27 mL/min, pZ 0.004 and cGFR: 77 22 mL/min/1.73 m2 vs. 96 24 mL/min/
1.73 m2, pZ 0.007). There was a negative correlation between GFR/cGFR and TFC in all coro-
nary arteries. This study shows that impaired renal function is associated with SCF. Patients
with SCF have worse renal function compared with patients without SCF.
Copyright ª 2011, Elsevier Taiwan LLC. All rights reserved.of Cardiology, Gaziosmanpasa
okat, Turkey.
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Slowcoronaryflow (SCF) is definedas lateopasification at the
epicardial coronary arteries without stenosis, as shown by
coronary angiography [1,2]. According to selective coronary
angiography, SCF appears to have approximately a 1%
frequency [3]. The endothelium plays a critical role inved.
56 F. Koc et al.determining coronary blood flow and providing vascular
tone. However, the etiology of SCF is unknown. Several
studies have shown that restingmicrovascular resistance and
flow-mediated dilatation (FMD) are deteriorated in SCF
patients [4e6].Other potential causes of SCFare small vessel
disease, diffuse atherosclerosis, platelet dysfunction,
microvascular dysfunction, and vasomotor dysfunction [1,7].
Studies showed that end-stage renal disease is associated
with endothelial dysfunction [8e13].
The purpose of this study was to investigate the rela-
tionship between renal functions and thrombolysis in
myocardial infarction frame count (TFC) in patients with
and without SCF.
Methods
Study population
The study population was taken from a series of 1,881
consecutive patients who underwent coronary angiography
in our unit between 2008 and 2010 because of the presence of
typical angina or angina-like symptoms. Out of the 1,881
patients, 34 patients who had angiographically normal
coronary arteries with SCF were enrolled in our study as well
as 34 consecutive age- and sex-matched controls with
angiographically normal coronary arteries and no SCF.
Normal coronary arteries were defined as coronary arteries
without any obstructive or nonobstructive lesions in the left
anterior descending coronary artery (LAD), left circumflex
coronary artery (LCX), and right coronary artery (RCA).
Coronary angiograms were analyzed by two expert cardiol-
ogists who were blinded to the patients’ data. Patients with
a history of coronary artery disease, heart failure, uncon-
trolled hypertension, and systemic disorders were excluded
from the study. We determined the presence of diabetes
mellitus by looking for a history of antidiabetic drug therapy
or by a fasting glucose level greater than 126 mg/dL.
Hypertension was diagnosed as blood pressure greater than
140/90 mmHg or use of antihypertensive therapy. Hyperlip-
idemia was defined as total cholesterol above 200 mg/dL or
low-density lipoprotein cholesterol above 130 mg/dL or
a history of statin use. Patientswho had been smoking before
the studywere accepted and listed as smokers. Approval was
obtained from the local ethics committee and informed
consent was obtained from all patients
Coronary angiography
Coronary angiography was performed using Judkin’s tech-
niques. Coronary arteries were visualized in left and right
oblique planes with cranial and caudal angles at a speed of
30 frames/s. An injection of 5e8 mL of contrast medium
(Iopromide; Ultravist-370 Schering AG, Berlin, Germany) was
given manually at each position. Coronary blood flow was
quantified by two independent observers who were blinded
to the clinical data. Coronary flow rates of all subjects were
documented by TFC. The TFC for each coronary artery was
determined according to a distal marking point specific for
the coronary artery of interest [14]. Diagnosis of SCF was
established as previously described [15].Biochemical measurements
Blood samples were drawn from an antecubital vein before
coronary angiography after a 12-hour overnight fast. Blood
urea nitrogen (BUN), creatinine, and other biochemical
parameters were determined by standard methods.
Glomerular filtration rate (GFR) was measured by creatinine
clearance according to the Cockcroft-Gault [16] formula.
The corrected GFR (cGFR) was calculated using the Cock-
croft-Gault formula adjusted for body surface area [17].
Statistical analysis
All statistical analyses were performed using SPSS for
Windows version 15 (SPSS Inc., Chicago, IL, USA). Values for
continuous variables were expressed as mean standard
deviation and categorical variables were written as
a percentage. Continuous data were compared using the
“Student t test” or “Mann-Whitney U test” and categorical
data via the “chi-squared test” or “Fisher’s Exact test.” The
associations between TFC and renal parameters were
determined by the Pearson or Spearman correlation test.
Statistical significance was defined as p< 0.05.
Results
There were no differences between patients with and
without SCF in gender (24 male vs. 19 male, pZ 0.14) and
age (56 11 years vs. 53 9 years, pZ 0.22). The risk
factors for coronary artery disease were similar between
the groups (Table 1). In the SCF group, TFC in LAD, LCX, and
RCA was significantly higher than the normal coronary
artery group. The renal function parameters were signifi-
cantly different between the two groups. Patients with SCF
have higher BUN and creatinine and lower GFR and cGFR
(Table 2). There was a negative correlation between GFR
and LAD TFC (rZ0.28; pZ 0.02), LCX TFC (rZ0.30;
pZ 0.01), and RCA TFC (rZ0.28; pZ 0.02). Also, there
was negative correlation between cGFR and LAD TFC
(rZ0.29; pZ 0.05), LCX TFC (rZ0.33; pZ 0.03), and
RCA TFC (rZ0.35; pZ 0.02).
Discussion
In the present study, we found that BUN, creatinine, GFR,
and cGFR are significantly different between patients with
and without SCF. There is a negative correlation between
the GFR/cGFR and TFC of each epicardial coronary artery.
TFC is a widely used method for the evaluation of
coronary blood flow. It also gives important information
about microvascular function and dysfunction in patients
with microvascular angina [18e20]. FMD is a simple method
that is used to evaluate endothelial function [21]. In the
study by Sezgin et al. [6], it was found that brachial artery
FMD is impaired in patients with SCF and observed that
there is an important relationship between FMD and TFC. In
previous studies, it has been reported that nitric oxide (NO)
is an important regulator of coronary circulation [22e24].
In the study by Sezgin et al. [25], it was found that NO
Table 1 Demographic and clinical characteristics of participants with slow coronary flow and normal coronary flowa
Variables Slow coronary flow
(nZ 34)
Normal coronary flow
(nZ 34)
p
Age, yr 56 11 53 9 0.22
Male 24 (70) 19 (55) 0.14
CAD risk factors
Hypertension 18 (53) 20 (59) 0.63
Hyperlipidemia 9 (26) 13 (38) 0.31
Diabetes 6 (18) 4 (12) 0.50
Smoking 10 (29) 6 (18) 0.26
Family history 9 (26) 6 (18) 0.39
Laboratory findings
Fasting glucose (mg/dL) 100 34 101 14 0.95
Total cholesterol (mg/dL) 206 33 199 36 0.45
LDL-cholesterol (mg/dL) 131 27 130 30 0.95
HDL-cholesterol (mg/dL) 42 10 40 10 0.44
Triglycerides (mg/dL) 171 97 143 55 0.20
Medications
Aspirin 29 (85) 25 (74) 0.37
ACEI/ARB 19 (56) 18 (53) 0.80
Beta blockers 7 (21) 4 (12) 0.51
Calcium antagonists 5 (15) 8 (24) 0.54
Nitrates 3 (9) 3 (9) 1
Statin 11 (32) 6 (18) 0.26
TIMI frame counts
LAD 40.8 8.7 25.6 4.3 0.001
LCX 31.0 7.9 18.4 3.5 0.001
RCA 26.3 5.4 15.6 1.9 0.001
Mean 29 6 18 3 0.001
a Data are presented as n(%) or mean  standard deviation.
ACEIZ angiotensin converting enzyme inhibitor; ARBZ angiotensin II receptor blocker; CADZ coronary artery disease; HDLZ high-
density lipoprotein; LADZ left anterior descending coronary artery; LCXZ left circumflex coronary artery; LDLZ low-density lipo-
protein; RCAZ right coronary artery; TIMIZ thrombolysis in myocardial infarction.
Table 2 Renal parameters of participants with slow coronary flow and normal coronary flowa
Variables Slow coronary flow
(nZ 34)
Normal coronary flow
(nZ 34)
p
BUN (mg/dL) 17 6 14 4 0.04
Creatinine (mg/dL) 0.90 0.19 0.79 0.16 0.01
GFR (mL/min) 92 28 112 27 0.004
cGFR (mL/min/1.73 m2) 77 22 96 24 0.007
a Data are presented as mean  standard deviation.
BUNZ blood urea nitrogen; cGFRZ corrected glomerular filtration rate; GFRZ glomerular filtration rate.
The renal functions in slow coronary flow 57levels are significantly lower in SCF patients than in normal
coronary artery patients and that NO is inversely correlated
with TFC.
Several studies have shown that there is a relationship
between coronary TFC and the previously determined
parameters of endothelial dysfunction in SCF patients
[26e30]. The deterioration of NO activity has been
reported to have an important impact on the renal
functions of both healthy and sick individuals because
endothelial dysfunction develops before significant
vascular disease [10]. It has been demonstrated that
there is endothelial dysfunction in the patients who haveend-stage renal disease [9]. Kielstein et al. [11] have
found higher levels of asymmetric dimethylarginine in
patients who have end stage renal disease and athero-
sclerotic vascular disease than in those who do not have
vascular disease. Zoccali et al. [9] have found that plasma
asymmetric dimethylarginine concentrations are a strong
and independent predictor of overall mortality and
cardiovascular outcome in hemodialysis patients. Iliescu
et al. [12] showed that microcirculation disorders have an
important role in the development of renal disease in
pigs. Astrup et al. [13] demonstrated a significant rela-
tionship between endothelial dysfunction and GFR in
58 F. Koc et al.patients who have diabetic nephropathy. In another study,
Erzen et al. [31] found an important relationship between
brachial FMD and GFR. Similarly, we found a significant
correlation between GFR and TFC in three coronary
arteries in SCF patients.
Our results demonstrate that renal parameters are
significantly different between patients with and without
SCF. Also, there is a negative correlation between GFR and
TFC. However, further studies are needed both to evaluate
renal function differences in patients with SCF and to
investigate whether these differences depend on endo-
thelial dysfunction.
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